Regulus Therapeutics Inc.
RGLS · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $115,805 | $103,489 | $102,790 | $122,484 |
| - Cash | $49,460 | $38,528 | $26,373 | $17,184 |
| + Debt | $1,401 | $274 | $476 | $1,422 |
| Enterprise Value | $67,746 | $65,235 | $76,893 | $106,722 |
| Revenue | $0 | $340 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | -$85 | -$87 | -$90 | -$89 |
| % Margin | – | -25.6% | – | – |
| EBITDA | -$9,532 | -$12,691 | -$13,967 | -$10,888 |
| % Margin | – | -3,732.6% | – | – |
| Net Income | -$9,634 | -$12,791 | -$14,062 | -$11,036 |
| % Margin | – | -3,762.1% | – | – |
| EPS Diluted | -0.15 | -0.2 | -0.21 | -0.17 |
| % Growth | 25% | 4.8% | -23.5% | – |
| Operating Cash Flow | -$10,613 | -$11,845 | -$9,449 | -$11,637 |
| Capital Expenditures | $268 | $0 | -$28 | -$83 |
| Free Cash Flow | -$10,345 | -$11,845 | -$9,477 | -$11,720 |